Table (1): Some demographic and clinical characteristics of studied groups

Characteristics	**Easy to treat group, N=68**	**Difficult to treat group, N=67**	**P value**
Age (years) Mean ± SD	49.38±12.72	50.29±11.26	0.66
Gender ; Male/Female	50 (73.5%) / 18 (26.5%)	40 (59.7%) / 27 (40.3%)	0.14
BMI (kg/m^2) Mean ± SD	27.32±2.57	27.49±2.41	0.69
Cirrhotic patients: n (%)	0(0%)	31 (46.3%)	**0.000**
Diabetic patients: n (%)	8 (11.8%)	13 (19.4%)	0.24
Hypertensive patients: n (%)	6 (8.8%)	4 (5.9%)	0.74

Table (2): Treatment response in the studied patients

Treatment data	Summary statistics
Type of treatment: n (%), Dual/Triple	68 (50.37%)/67 (49.63%)
ETR: End of treatment response: n(%)	135 (100%)
Dual treatment: n (%) SVR 12/Relapser	67(98.52%)/1(1.48%)
Triple treatment: n (%) SVR 12/ Relpser	66 (98.50%) / 1 (1.49%)

N%: Number, percentage Dual: sofosubuvir with daclatasvir

Triple: sofosubuvir, daclatasvir with ribavirin ETR: End of treatment response

SVR12: Sustained virological response at 12 week post treatment follow up

Table (3): Criteria of relapsed cases

Characteristics	Case 1	Case 2
Age (years)	46	55
Gender	male	male
BMI (kg/m^2)	27	26
Previous treatment	Treatment naive	Treatment naive
Type of treatment	Triple	Dual
PCR at baseline (IU/ml)	9.6×10^6	79244
PCR at relapse (IU/ml)	21.6×10^6	158245
LSM (m/sec)	2.4 (F4)	1.69 (F3)

BMI: body mass index LSM: Liver stiffness measurement

Table (4):Laboratory data that measured at baseline, 4 week, end of treatment, and 12 week post treatment follow up (SVR12).

Investigation	Baseline	4 week	End of treatment	SVR12	P value
WBCs (10^9/l) Mean ± SD	6.35±2.54	6.25±2.11	6.10±2.05	6.16±1.93	0.58
Hamoglobin (g/dl) Mean ± SD	13.92±1.69	12.97±1.76	12.50±1.40	13.87±1.86	0.72
Platelets (10^9/l) Mean ± SD	200.58±74.51	197.25±63.71	197.06±64.86	206.26±72.25	0.22
T.bilirubin(mg/dl) Mean± SD	0.85±0.32	0.96±0.53	0.87±0.41	0.75±0.32	**0.0002*** **
ALT(IU/l) Mean ± SD	46.4±34.55	29.38±17.48	23.31±12.76	19.40±11.20	**<0.0001*** **
AST(IU/l) Mean ± SD	46.20±35.88	31.70±17.90	27.13±16.26	23.12±12.21	**<0.0001*** **

SD: Standard deviation IQR: Interquartile range

*** = highly significant ALT: Alanine aminotranseferase

AST: Aspartate aminotranseferase

Table (5): Other laboratory data that measured at baseline and at 12 week post treatment follow up (SVR12)

Investigation	Baseline	SVR12	P value
Serum albumin (g/dl) Mean ± SD	4.12±0.53	4.33±0.50	**<0.0001*** **
Prothrombin time (sec) Mean ± SD	12.76±1.40	12.16±1.26	**<0.0001*** **
Prothrombin concentration (%) Mean ± SD	87.79±12.99	91.26±11.25	**0.0001*** **
INR Mean ± SD	1.08±0.14	1.01±0.11	**<0.0001*** **

W: week SD: Standard deviation SVR12: Sustained virological response at 12 week post treatment follow

*** = highly significant Sec: second INR: International normalized ratio

Table (6): Adverse events of sofosbuvir based regimens in studied patients

Adverse events of treatment	Easy to treat group, N=68	Difficult to treat group, N=67	Total N=135	P value
Fatigue	25 (36.8%)	34 (50.7%)	59 (43.7%)	0.12
Headache	12 (17.6%)	18 (26.9%)	30 (22.22%)	0.22
Nausea and epigastric pain	9 (13.2%)	12 (17.9%)	21 (15.6%)	0.49
Itching	1 (1.5%)	0 (0%)	1 (0.74%)	1
Decreased appetite	1(1.5%)	2 (3%)	3 (2.2%)	0.62
Diarrhea	2 (2.9%)	3 (4.5%)	5 (3.7%)	0.68
Lower limb edema	0 (0%)	1(1.5%)	1 (0.74%)	1
Serious adverse events or death	0 (0%)	0 (0%)	0 (0%)	0